MSK Department of Medicine

Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer Osorio et al. report a first-in-human study of intratumoral 2141-V11, an Fc-engineered CD40 agonistic antibody, showing it is safe and induces systemic and durable antitumor immunity in patients with ...

Important translational and clinical work here using CD40 agonistic antibody in metastatic cancer @anatosaurus.bsky.social Cancer Cell www.cell.com/cancer-cell/... @mskcancercenter.bsky.social @mskdeptofmed.bsky.social

We're excited to share that we've been recognized as #1 in oncology on @newsweek.com's World's Best Specialized Hospitals List.

bit.ly/4nefIFv

Brachytherapy for Brain Metastases As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease.

MSK experts are investigating whether #brachytherapy may be an effective treatment option for reducing local recurrence, lowering the risk of #necrosis associated with standard #radiation, and improving the quality of life for patients with brain #metastases. Learn more ⬇️

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition Histiocytic neoplasms are clonal disorders of the monocyte/macrophage lineage defined by mutations activating mitogen-activated protein kinase (MAPK) …

Excited to announce a new publication from our @mskcancercenter.bsky.social Histiocytosis group identifying a predictor for impaired response to MEK inhibition in histiocytosis patients and potential for ERK inhibition. Out today in @Cancer_Cell.

www.sciencedirect.com/science/arti...

Memorial Sloan Kettering Cancer Center Physician-Scientist Elected to the Prestigious National Academy of Medicine Omar Abdel-Wahab, MD, Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI); Evnin Family Chair in Molecular Pharmacology and Attending Physician on the Leukemia Service at Me...

We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at MSK, has been elected to the @nam.edu.

With Dr. Abdel-Wahab’s appointment, a total of 28 MSK faculty members have been conferred with this recognition.

Congratulations, Dr. Abdel-Wahab!

bit.ly/49ezKw0

#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib plus pembrolizumab in advanced #endometrialcancer. @mskcancercenter.bsky.social

➡️ bit.ly/3JncnWA

ESMO 2025 Research Roundup: MSK Presents Exciting Advances in Medical Oncology Research MSK researchers presented exciting advances in medical oncology for a range of cancer types at the ESMO Congress 2025. Highlights included the latest updates on three phase 1 trials testing innovative...

MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myesmo.bsky.social Congress 2025 held in Berlin. Highlights include the latest updates on phase 1 trials testing innovative treatment approaches for select patients w/ advanced solid tumors and more:

This morning at #ESMO25, William Tap gave a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @mskcancercenter.bsky.social @myesmo.bsky.social

Learn more: bit.ly/47h3DJG

At #ESMO25, join Dr. Yonina Murciano-Goroff to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social

Learn more: bit.ly/4nafnUa

Happening NOW at #ESMO25: View Kenneth Yu's poster about a phase 1 trial of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells for stage 4 #pancreaticcancer or #breastcancer with an inherited BRCA/PALB2 mutation.
@mskcancercenter.bsky.social

Learn more: bit.ly/3KZ0iHw

At #ESMO25, Rebecca Dent will present the results of a phase 3 study of first-line datopotamab deruxtecan for those w/ inoperable or metastatic triple-negative #breastcancer. @mskcancercenter.bsky.social's Tiffany Traina is the senior author.

🗓️ October 19, 9:25 a.m. CEST

Learn more: bit.ly/4n5B8od

Happening tomorrow at #ESMO25: Helena Yu will share preliminary results from the ongoing phase 2b trial of zipalertinib in patients with non-small cell #lungcancer who have central nervous system #metastases. @mskcancercenter.bsky.social @myesmo.bsky.social

Learn more: bit.ly/3W74yY3

Happening next at #ESMO25: Yelena Janjigian will lead a session on how she and other experts are identifying new treatments to improve outcomes for those with gastroesophageal adenocarcinoma. @mskcancercenter.bsky.social @myesmo.bsky.social

Learn more: bit.ly/3WcyfH5

Don't miss the first presidential symposium at #ESMO25! Tomorrow, join @DrRosenbergMSK to hear his thoughts on a study of perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive #bladdercancer. @mskcancercenter.bsky.social

Learn more: bit.ly/42JM3ws

Tomorrow at #ESMO25, Dr. Vicky Makker will present at an education session about selecting the best first-line treatment based on molecular classification. @mskcancercenter.bsky.social @myesmo.bsky.social

Learn more: bit.ly/3W6rqqz

Tomorrow at #ESMO25, Violaine Randrian will present a study investigating whether the mechanism of mismatch repair protein loss impacts outcomes for those with solid tumors treated with #immunotherapy. @mskcancercenter.bsky.social

Learn more: bit.ly/4neLsu1

🗓️ October 18 | 11:10 a.m. CEST

Congratulations to Ross Levine on his new role as @mskcancercenter.bsky.social's Chief Scientific Officer!

Exciting research is ahead at #ESMO25! Tomorrow, Dr. Michael Foote will present interim safety and efficacy data of a phase 1/1b study of an investigational drug for people with advanced solid tumors. @mskcancercenter.bsky.social @myesmo.bsky.social

Learn more: bit.ly/4qrq3Rg

How Routine Prenatal Tests Can Detect Cancer and What It Means for Pregnant Women Learn how noninvasive prenatal tests designed to screen for genetic abnormalities in the fetus may detect the presence of cancer in pregnant women.

This case study underscores the emerging potential of noninvasive prenatal testing (NIPT), a technology developed to screen for fetal conditions but now being studied for its ability to detect cancer. Learn more ⬇️

🎥 At #SOHO2025, Ariela Noy of @mskcancercenter.bsky.social shared insights into the management of Burkitt #lymphoma, highlighting the need to improve frontline treatment.

Watch here:
👉 buff.ly/kp1MrVH 👈

#LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky @societyofhemonc.bsky.social

Join us for MSK's 2025 Health Equity in Cancer Care Conference on Friday, November 14. This complimentary one-day event will unite experts from across fields, institutions, and specialties to explore actionable strategies for advancing #healthequity in underserved populations.

Cancer research means bigger breakthroughs, on a faster timeline, that improve the lives of people impacted by cancer. Today is World Cancer Research Day & all donations will be DOUBLED.

Donate today & help bring more possibilities to families facing cancer. bit.ly/46mefYy #WorldCancerResearchDay

The Latest Radiation Therapy for Prostate Cancer: What Every Man Should Know It can be hard to understand all the various radiation therapy options for prostate cancer. Here, we explain.

Radiation therapy for prostate cancer is more precise, convenient, and personalized than ever before. From #SBRT to MRI-guided and adaptive approaches, MSK experts are leading advances that improve outcomes and protect quality of life for patients with #prostatecancer. ⬇️

At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm

🗓️ Saturday, September 20 | 9:20 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social

Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm

🗓️ Friday, September 19 | 9:40 a.m. EDT

@mskcancercenter.bsky.social @myeloma-society.bsky.social

Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma.

🗓️ Thursday, September 18 | 4:40 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma.

🗓️ Wednesday, September 17 | 12:14 p.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm

🗓️ Wednesday, September 17 | 11:10 a.m. EDT

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm

@mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Starting TODAY! Join @greatdebates.bsky.social
and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer.

@mskcancercenter.bsky.social #crcsm #GIcancer

See the full agenda 📖: bit.ly/48g13pf